Abstract
Epigenetic modifications play central roles in cellular differentiation and their deregulations really contribute to tumor development. Histone deacetylase (HDAC) enzymes can exert their functions in the epigenetic regulation of gene expression related to oncogenesis via deacetylating the lysine residues of histones in the chromatin and various non-histone proteins. A majority of HDAC inhibitors (HDACIs) have been in different stages of preclinical and clinical trials with potent anticancer activity recently. Among these agents, chidamide tested as either monotherapeutic agent or in combination regimens for numerous hematological and solid malignancies has shown promising potential as an orally active subtype-selective HDACI. Herein we will highlight the progress of clinical trials of chidamide and rationally analyze those results from both preclinical and clinical studies about chidamide as an epigenetic modulator in cancer therapy.
Keywords: Epigenetic, histone deacetylase inhibitors, chidamide, hematologic and solid cancers, preclinical and clinical trials.
Graphical Abstract
Anti-Cancer Agents in Medicinal Chemistry
Title:Preclinical and Clinical Studies of Chidamide (CS055/HBI-8000), An Orally Available Subtype-selective HDAC Inhibitor for Cancer Therapy
Volume: 17 Issue: 6
Author(s): Shuai Gao, Xiaoyang Li, Jie Zang, Wenfang Xu*Yingjie Zhang*
Affiliation:
- Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Shandong University, 44 West Culture Road, 250012 Ji'nan, Shandong,China
- Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Shandong University, 44 West Culture Road, 250012 Ji'nan, Shandong,China
Keywords: Epigenetic, histone deacetylase inhibitors, chidamide, hematologic and solid cancers, preclinical and clinical trials.
Abstract: Epigenetic modifications play central roles in cellular differentiation and their deregulations really contribute to tumor development. Histone deacetylase (HDAC) enzymes can exert their functions in the epigenetic regulation of gene expression related to oncogenesis via deacetylating the lysine residues of histones in the chromatin and various non-histone proteins. A majority of HDAC inhibitors (HDACIs) have been in different stages of preclinical and clinical trials with potent anticancer activity recently. Among these agents, chidamide tested as either monotherapeutic agent or in combination regimens for numerous hematological and solid malignancies has shown promising potential as an orally active subtype-selective HDACI. Herein we will highlight the progress of clinical trials of chidamide and rationally analyze those results from both preclinical and clinical studies about chidamide as an epigenetic modulator in cancer therapy.
Export Options
About this article
Cite this article as:
Gao Shuai, Li Xiaoyang, Zang Jie, Xu Wenfang*, Zhang Yingjie*, Preclinical and Clinical Studies of Chidamide (CS055/HBI-8000), An Orally Available Subtype-selective HDAC Inhibitor for Cancer Therapy, Anti-Cancer Agents in Medicinal Chemistry 2017; 17 (6) . https://dx.doi.org/10.2174/1871520616666160901150427
DOI https://dx.doi.org/10.2174/1871520616666160901150427 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
DYRK1A Kinase Inhibitors with Emphasis on Cancer
Mini-Reviews in Medicinal Chemistry Lipid Nucleoside Conjugates for the Treatment of Cancer
Current Pharmaceutical Design Clinical Trials in Chemoprevention of Head and Neck Cancers
Reviews on Recent Clinical Trials Recent Patents and Patent Applications Relating to mTOR Pathway
Recent Patents on DNA & Gene Sequences The Novel RARβ Isoform (β 5) is a Potential Target of Retinoids in Breast Cancer
Current Cancer Drug Targets Medicinal Plants Towards Modeling Skin Cancer
Current Drug Targets Drug-Eluting Stents: Present and Future
Cardiovascular & Hematological Agents in Medicinal Chemistry Advances in Liver-Directed Gene Therapy for Hepatocellular Carcinoma by Non-Viral Delivery Systems
Current Gene Therapy Implication of Heat Shock Protein 90 (HSP90) in Tumor Angiogenesis: A Molecular Target for Anti-Angiogenic Therapy?
Current Cancer Drug Targets P53 Gene Therapy Sensitizes Resistant Breast Cancer Cells to Doxorubicin Chemotherapy
Drug Delivery Letters Modulation of ABC Transporters by Nuclear Receptors: Physiological, Pathological and Pharmacological Aspects
Current Medicinal Chemistry Novel Therapeutic Approaches to Regulate Human Dihydrofolate Reductase Activity and Expression
Current Enzyme Inhibition Chemopreventive Properties and Molecular Mechanisms of the Bioactive Compounds in Hibiscus Sabdariffa Linne
Current Medicinal Chemistry Nanotechnology and Animal Health
Pharmaceutical Nanotechnology Supplements, Diets and Other Complementary and Alternative Interventions in Adolescent Mental Health
Adolescent Psychiatry Targeting Translation for Treatment of Cancer - A Novel Role for IRES?
Current Cancer Drug Targets Improving Cancer Therapeutics by Molecular Profiling
Current Drug Metabolism Preface
Current Pharmaceutical Design The “Big Five” Phytochemicals Targeting Cancer Stem Cells: Curcumin, EGCG, Sulforaphane, Resveratrol and Genistein
Current Medicinal Chemistry C-KIT Signaling in Cancer Treatment
Current Pharmaceutical Design